Millennium reports results from two VELCADE based combination studies against multiple myeloma

April 13, 2017

A phase Ib study of oral panobinostat and IV bortezomib in relapsed and refractory multiple myeloma

This Phase Ib study of 62 relapsed or relapsed and refractory multiple myeloma patients assessed the safety and efficacy of VELCADE in combination with panobinostat. Forty-five percent of patients had received prior treatment with VELCADE, and 31 percent were refractory to VELCADE. The results, which were presented by Jesus San Miguel, M.D., Ph.D., Hospital Universitario de Salamanca, showed:

Maximum tolerated dose was established as 20 mg of panobinostat plus 1.3 mg/m2 of VELCADE The most common grade 3/4 adverse events were thrombocytopenia (79 percent), neutropenia (55 percent) and leukopenia (30 percent) Across all dosing cohorts, ORR was 55 percent Among VELCADE-refractory patients, ORR was 42 percent

This phase Ib study of relapsed or relapsed and refractory multiple myeloma completed enrollment>2 VELCADE. In the expansion phase, 15 patients received the MTD of panobinostat and VELCADE, with a modified panobinostat schedule (2 weeks on, 1 week off) and dexamethasone introduced for all patients at C2. This is identical to the dose and schedule in the ongoing phase II and III PANORAMA trials. (Abstract #8075)

Source: Millennium: The Takeda Oncology Company